The FTSE 100 took a downturn on Friday, with mining and pharmaceutical stocks dragging it down, while mid-cap companies saw modest gains. This mixed performance left analysts pondering whether it's a summer lull or a more significant trend. David Morrison, a senior analyst at Trade Nation, warns that the momentum in London is shifting downward, marking a pause in a summer rally that pushed European indices to record highs. The question now is whether this is a top for these indices or a temporary dip. The market's focus is on US indices, with softer inflation readings and disappointing payroll data potentially easing Fed rate hike expectations, which has supported equities. However, European investors remain vigilant about energy prices as summer wanes.
In other news, the CAC 40 in Paris and the DAX 40 in Frankfurt closed with slight losses and gains, respectively, while New York stocks were weaker, with the Dow Jones Industrial Average, S&P 500 index, and Nasdaq Composite all experiencing declines. The surprise drop in US retail sales further complicates the interest rate debate, as soft inflation readings suggest a potential pause in rate hikes at the September Federal Open Market Committee meeting. The greenback weakened across the board, with the pound, euro, and yen experiencing fluctuations.
In London, Entain rose 2.1% after strong revenue figures, while Aviva saw a 1.8% increase following robust first-half results. However, Antofagasta fell sharply, and drug stocks GSK and AstraZeneca also took a hit. On the FTSE 250, recruiters Michael Page and Hays continued their upward trajectory, with Michael Page receiving a boost from UBS's upgrade. Conversely, GB Group's shares sank 31% due to revenue growth guidance cuts. Cohort, a defense technology company, climbed 6.1% after securing a significant contract from Saab.
Looking ahead, the market's attention turns to China's industrial production and retail sales figures, Japan's GDP print, and Canada's inflation report on Monday. The UK corporate calendar features full-year results from Optima Health. As the week progresses, investors will closely monitor these economic indicators and corporate developments, seeking to navigate the complexities of the global financial landscape.
